 | 09/08/2010 09:50:15 AM
ENOBIA PROVIDES UPDATE ON PROGRESS WITH ENB-0040, A BONE-TARGETED ENZYME REPLACEMENT THERAPY FOR HYPOPHOSPHATASIA
- Key Composition of Matter Patent Issued for Investigational Treatment -- Phase 2 Data to be Presented at Upcoming Scientific Meetings - Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040, an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia.
[Canada Newswire] |
| 09/08/2010 09:46:17 AM
EDAP Reports Publication of Long-Term Clinical Results for Largest Cohort of Ablatherm-HIFU Patients Favorable Clinical Outcomes for Prostate Cancer Patients Treated Over 15 Years
EDAP TMS SA, the global leader in therapeutic ultrasound, today reported favorable clinical outcomes for patients treated with Ablatherm-HIFU. This French multi-centric study reports the largest series of patients who have been followed for the longest amount of time.
[GlobeNewswire] |
| 09/08/2010 09:30:10 AM
ACR Image Metrix Enhances Website with New Educational Features For Imaging in Clinical Research
ACR Image Metrix, an imaging contract research organization with expertise in imaging research design, techniques and data extraction, is pleased to announce the launch of its enhanced website, www.acr-imagemetrix.net. With a new appearance and increased functionality, ACR Image Metrix aimed to extend awareness of its new educational features on their website.
[Business Wire] |
| 09/08/2010 09:18:04 AM
GE Announces Phase 2 Flutemetamol Results
GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology. The purpose of the phase 2 study was to investigate the efficacy of flutemetamol in differentiating between patients with clinically probable Alzheimer's disease and cognitively intact healthy volunteers.
[Benzinga] |
| 09/08/2010 09:06:04 AM
Vertex Reports Solid REALIZE Data
Vertex Pharmaceuticals, Inc. reported results from phase 3 of the REALIZE trial in treatment experienced genotype 1 HCV patients, and is expecting approval in 2011, thanks in part to data that is right now only marginally better than its competitors, JP Morgan reports.
[Benzinga] |
| 09/08/2010 09:05:00 AM
PolyMedix to Present Antibiotic Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Five Poster Presentations with Results from Antimicrobial Studies Including PolyMedix's Phase 1B Clinical Trial with PMX-30063. PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, will be presenting five posters at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
[Business Wire] |
| 09/08/2010 09:00:37 AM
Current Clinical Findings on the Therapeutic Use of Concentrated Bone Marrow-Derived Stem Cells Will be Presented During ThermoGenesis Symposium at Leading Cellular Therapy Meeting in Europe
RANCHO CORDOVA, Calif., Sept. 8 ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today that findings from the use of concentrated bone marrow-derived stem cells in orthopedic and Critical Limb Ischemia applications will be presented at the upcoming International Stem Cell Therapy-Europe regional meeting in Belgirate, Italy.
[PR Newswire] |
| 09/08/2010 09:00:15 AM
Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology Phase 3 Studies In Progress
PRINCETON, N.J., Sept. 7 GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology. The purpose of the phase 2 study was to investigate the efficacy of flutemetamol in differentiating between patients with clinically probable Alzheimer's disease and cognitively intact healthy volunteers.
[PR Newswire] |
| 09/08/2010 09:00:12 AM
BioMarin to Present at the Robert W. Baird Healthcare Conference
NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Robert W. Baird Healthcare Conference in New York City on Wednesday, September 15, 2010 at 10:30 a.m. ET.
[PR Newswire] |
| 09/08/2010 09:00:09 AM
Telerik Puts ATSIP Interpretive Centre on Fast Track to Excellence
RadControls saves Australian Tropical Sciences and Innovation Precinct hundreds of development hours across project life.
[Business Wire] |
| 09/08/2010 08:45:10 AM
Applied Nanotech Selected for Phase II Award by Department of Energy to Develop Carbon Foils for Ion Beam Accelerators
Applied Nanotech Holdings, Inc. is pleased to announce that it has been notified that it has been selected for a SBIR Phase II award to develop carbon foils for the next generation ion beam accelerators.
[GlobeNewswire] |
| 09/08/2010 08:30:29 AM
Curaxis Pharmaceutical Corp CEO Patrick S. Smith Announces Plans for Further Clinical Trials for Alzheimer's Treatment
Curaxis Pharmaceutical Corp today announced an update on the Company's clinical development plans for Memryte, its candidate to treat mild-to-moderate Alzheimer's disease.
[GlobeNewswire] |
| 09/08/2010 08:30:27 AM
Aastrom to Present at 12th Annual Rodman & Renshaw Global Investment Conference
Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Tim Mayleben, president and CEO, will present at the 12th Annual Rodman & Renshaw Global Investment Conference. A live webcast of Aastrom's presentation can be accessed by logging onto the web at http://www.wsw.com/webcast/rrshq18/astm.
[GlobeNewswire] |
| 09/08/2010 08:30:26 AM
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
NEW YORK, Sept. 8 Keryx Biopharmaceuticals, Inc. today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following investor conferences: A live audio webcast of Mr. Bentsur's presentations will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each webcast will be available f...
[PR Newswire] |
| 09/08/2010 08:30:24 AM
ImmunoCellular Therapeutics Announces Long-Term Disease-Free Survival Data from Phase I Study in Glioblastoma
Novel Cancer Vaccine Demonstrates Significantly Superior Two- and Three-Year Disease-Free Survival Rates Compared to Historical Controls.
[Business Wire] |
| |
previous
|
next |
